Vitamin D-3 supplementation and neurofilament light chain in multiple sclerosis
| العنوان: | Vitamin D-3 supplementation and neurofilament light chain in multiple sclerosis |
|---|---|
| المؤلفون: | Jens Kuhle, Joost Smolders, Jody van den Ouweland, Max Mimpen, Jan Damoiseaux, Raymond Hupperts, Johanna Oechtering |
| المساهمون: | Netherlands Institute for Neuroscience (NIN), Faculteit FHML Centraal, RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: DA CDL Algemeen (9) |
| المصدر: | Acta Neurologica Scandinavica, 141(1), 77-80. Wiley-Blackwell Acta Neurologica Scandinavica, 141(1), 77-80. Wiley |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Vitamin, medicine.medical_specialty, Neurofilament light, BETA, vitamin D, Placebo, multiple sclerosis, DISEASE-ACTIVITY, Gastroenterology, Placebo group, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Vitamin D and neurology, 030212 general & internal medicine, EPSTEIN-BARR-VIRUS, Plasma samples, business.industry, Multiple sclerosis, General Medicine, medicine.disease, 25-hydroxyvitamin D, neurofilament light chain, Neurology, chemistry, supplementation, Biomarker (medicine), TRIAL, Neurology (clinical), business, 030217 neurology & neurosurgery |
| الوصف: | Objectives: Low circulating vitamin D levels are associated with an increased risk of active MRI lesions and relapses in several cohorts with relapsing remitting multiple sclerosis (RRMS). Randomized controlled supplementation trials are, however, negative on their primary endpoints, while secondary MRI endpoints suggest anti-inflammatory effects. Circulating levels of neurofilament light chain (NfL) are a biomarker of disease activity in RRMS. We explored whether 48-week high-dose vitamin D 3 supplements were associated with lower circulating NfL levels. Materials & Methods: Of N = 40 Dutch interferon beta-treated participants with RRMS of the SOLAR trial, plasma samples at baseline and 48-week follow-up were available. Of these participants, N = 24 were supplemented with 14 000 IU/d vitamin D 3 and N = 16 with placebo. Twenty-five hydroxyvitamin D 3 (25(OH)D 3) levels were measured with LC-MS/MS, and NfL levels were measured in duplicate with Simoa. Results: Serum 25(OH)D 3 levels at 48 weeks were increased in the vitamin D 3 when compared to placebo group (median level 281 [IQR 205-330] vs 72 [39-88] nmol/L; P 3 for 48 weeks was not associated with lower NfL levels. This study does not support an effect of vitamin D 3 on this biomarker of neuro-axonal injury. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0001-6314 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::656f470b230af7d233051ffd4614208cTest https://doi.org/10.1111/ane.13185Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....656f470b230af7d233051ffd4614208c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00016314 |
|---|